On June 17, Boan Bio (06955) issued an announcement, announcing that its independently developed innovative antibody-drug conjugate BA1302 targeting CD228 has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials.

　　The drug is intended for the treatment of a variety of solid tumors and has been granted orphan drug designation by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, BA1302 is undergoing Phase 1 clinical trials in China, and its global progress is ahead of other similar research and development efforts.

　　BA1302 has shown excellent internalization activity and bystander effects in preclinical studies, and can effectively inhibit the growth of tumor models derived from various cancer patients, showing good therapeutic potential. In addition, compared with the marketed ADCs with MMAE as toxin, BA1302 has shown a longer half-life and better safety in crab-eating monkeys. The company will accelerate the global development of BA1302, explore its clinical application value in more indications, and bring new treatment hope to patients around the world.

https://finance.eastmoney.com/a/202506173432628853.html